SLC44A3: A Potential Drug Target Or Biomarker (G126969)

Target Name: SLC44A3

NCBI ID: G126969

SLC44A3

SLC44A3: A Potential Drug Target Or Biomarker

SLC44A3, also known as SLC44A3 gene, is a member of theSolute carrier family 44 and located on chromosome 1p36.3. It is a gene that encodes a protein known as SLC44A3, which is a carrier protein for a type of sugar called disaccharide maltose. TheDisaccharide maltose is a type of sugar that is commonly used in laboratory research and in the treatment of certain diseases.

SLC44A3 gene is a gene that has been identified as a potential drug target or biomarker. The protein encoded by this gene has been shown to play a role in the transportation of various molecules across cell membranes, including glucose and other sugar molecules. Several studies have suggested that alterations in the levels of SLC44A3 protein or its function could be involved in a variety of diseases, including diabetes, cardiovascular disease, and neurodegenerative disorders.

One of the key features of SLC44A3 protein is its ability to transport glucose across cell membranes. Glucose is an essential sugar that is used by the body for energy metabolism, and it is also involved in the regulation of various cellular processes. SLC44A3 protein has been shown to play a critical role in the transport of glucose across the cell membrane, allowing it to be used as a potential drug target or biomarker for diseases that involve the regulation of glucose metabolism.

In addition to its role in glucose transport, SLC44A3 protein has also been shown to play a role in the regulation of other types of molecules. For example, this protein has been shown to be involved in the transport of amino acids across the cell membrane, which are essential for the maintenance of cellular proteins and other molecules.

Another promising aspect of SLC44A3 protein is its potential to serve as a drug target or biomarker for certain neurodegenerative disorders. Several studies have suggested that alterations in the levels of SLC44A3 protein or its function could be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

One of the key challenges in studying SLC44A3 protein is its relatively high stability, as it is a carrier protein that is expressed in high levels in most tissues. This makes it difficult to study the function of this protein in specific contexts, such as the regulation of glucose metabolism or the regulation of other types of molecules. However, researchers are continuing to study the function of SLC44A3 protein and its potential as a drug target or biomarker for various diseases.

In conclusion, SLC44A3 gene is a member of theSolute carrier family 44 that encodes a protein known as SLC44A3. This protein has been shown to play a role in the transportation of various molecules across cell membranes, including glucose and other sugar molecules. Several studies have suggested that alterations in the levels of SLC44A3 protein or its function could be involved in a variety of diseases, including diabetes, cardiovascular disease, and neurodegenerative disorders. Further research is needed to fully understand the function of SLC44A3 protein and its potential as a drug target or biomarker for these diseases.

Protein Name: Solute Carrier Family 44 Member 3

The "SLC44A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC44A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets